t-Butyl (4-bromoacetylphenyl)oxyacetate | 165947-77-3

• 英文名称: t-Butyl (4-bromoacetylphenyl)oxyacetate
• 英文别名: tert-butyl 4-bromoacetylphenoxyacetate；t-butyl 4-bromoacetylphenoxyacetate；Tert-butyl 2-[4-(2-bromoacetyl)phenoxy]acetate
• CAS: 165947-77-3
• 化学式: C₁₄H₁₇BrO₄
• 分子量: 329.191
• InChiKey: KYUHWCNPQANFCF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  t-Butyl (4-bromoacetylphenyl)oxyacetate 以 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 以1.707 g (100%)的产率得到t-butyl (4-azidoacetylphenyl)oxyacetate
  参考文献：
  名称：

  EP897920

  摘要：

  公开号：

文献信息

• Heterocyclic derivatives
  申请人：Zeneca Limited

  公开号：US05556977A1

  公开（公告）日：1996-09-17

  Compounds of formula I ##STR1## and metabolically labile esters and amides thereof, and pharmaceutically acceptable salts thereof, in which R.sup.13, M.sup.2, X.sup.1, Z.sup.1, Z.sup.1a, X.sup.2 and A.sup.1 have the meanings given in the specification. The compounds are useful as inhibitors of the binding of fibrinogen to glycoprotein IIb/IIIa. Intermediates are also disclosed.

  公式I的化合物及其代谢易降解的酯和酰胺，以及其药学上可接受的盐，其中R.sup.13，M.sup.2，X.sup.1，Z.sup.1，Z.sup.1a，X.sup.2和A.sup.1具有规范中给定的含义。这些化合物可用作抑制纤维蛋白原与糖蛋白IIb/IIIa结合的抑制剂。还披露了中间体。
• Heterocyclic compouds
  申请人：Zeneca Limited

  公开号：US05753659A1

  公开（公告）日：1998-05-19

  A compound of the general formula (M.sup.1).sub.n --Q--(M.sup.2).sub.1-n --L--A I wherein: n is 0 or 1; M.sup.1 is an amino group; Q is an aromatic heterocyclic group containing a basic nitrogen atom; M.sup.2 is an imino group; L is a template group; and A is an acidic group, or an ester or amide derivative thereof, or a sulphonamide group; and pharmaceutically acceptable salts and pro-drugs thereof, for use in the treatment of a disease in which platelet aggregation mediated by the binding of adhesion molecules to GPIIb-IIIa is involved. Novel compounds are also disclosed.

  通式（M.sup.1).sub.n --Q--(M.sup.2).sub.1-n --L--A I的化合物，其中：n为0或1；M.sup.1为氨基；Q为含有碱性氮原子的芳香杂环基团；M.sup.2为亚胺基；L为模板基团；A为酸性基团，或其酯或酰胺衍生物，或磺酰胺基团；以及其药学上可接受的盐和前药，用于治疗通过粘附分子结合到GPIIb-IIIa介导的血小板聚集参与的疾病。还披露了新的化合物。
• NOVEL COMPOUND HAVING PLATELET AGGREGATION INHIBITOR EFFECT
  申请人：MEIJI SEIKA KABUSHIKI KAISHA

  公开号：EP0721941A1

  公开（公告）日：1996-07-17

  A compound represented by general formula (I) and having a platelet aggregation inhibitor effect and pharmacologically acceptable salt and solvate thereof, wherein A, B and C represent each CH2 or C=O; X and Y are different from each other and represent CH or N; D represents -(CH2)k- or -(CH2)m-CO-, wherein k represents an integer of 1 to 4, and m represents an integer of 0 to 3; E represents group (II) or (III), wherein n represents an integer of 1 to 3, Z represents -W-(CH2)p-COOR3, W represents -O- or a bond, p represents an integer of 1 to 4, and R3 represents hydrogen, lower alkyl or an ester residue eliminable under physiological conditions; R1 represents hydrogen or lower alkyl; and R2 represents hydrogen or lower alkyl.

  通式(I)代表的具有血小板聚集抑制作用的化合物及其药理学上可接受的盐和溶液，其中A、B和C分别代表CH2或C＝O；X和Y互不相同，代表CH或N；D代表-( )k-或-( )m-CO-，其中k代表1至4的整数，m代表0至3的整数；E 代表基团(II)或(III)，其中 n 代表 1 至 3 的整数，Z 代表-W-( )p-COOR3，W 代表-O-或键，p 代表 1 至 4 的整数，R3 代表氢、低级烷基或在生理条件下可消除的酯残基；R1 代表氢或低级烷基；R2 代表氢或低级烷基。
• NOVEL HETEROCYCLIC COMPOUNDS HAVING PLATELET AGGREGATION INHIBITORY EFFECTS
  申请人：MEIJI SEIKA KABUSHIKI KAISHA

  公开号：EP0897920A1

  公开（公告）日：1999-02-24

  Disclosed are a compound represented by the following formula (I) and pharmacologically acceptable salt and solvate thereof having inhibitory activity against platelet aggregation:    wherein A represents the following formula (II), (III), or (IV): A pharmaceutical composition comprising the above compound can be utilized as a platelet aggregation inhibitor that possesses excellent inhibitory activity against platelet aggregation, is free from hemorrhage and other side effects such as those derived from selectivity for the inhibitory action, and is potent against vasculature lesions, such as vasospasm.

  本发明公开了具有血小板聚集抑制活性的下式(I)代表的化合物及其药理学上可接受的盐和溶液： 其中 A 代表下式 (II)、(III) 或 (IV)： 由上述化合物组成的药物组合物可用作血小板聚集抑制剂，该药物对血小板聚集具有极佳的抑制活性，无出血和其他副作用，如抑制作用的选择性所产生的副作用，并对血管痉挛等血管病变具有强效作用。
• NOVEL COMPOUND WITH PLATELET AGGREGATION INHIBITOR ACTIVITY
  申请人：MEIJI SEIKA KABUSHIKI KAISHA

  公开号：EP0641770B1

  公开（公告）日：1998-05-13